Compare ARK Fintech Innovation ETF (ARKF) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Sana Biotechnology Inc — how do they compare? ARK Fintech Innovation ETF trades at $41.45, while Sana Biotechnology Inc trades at $3.69 (market cap $1.07B). Which is the better fit depends on your goals.
| ARKF | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $5.92 |
52-Week Low | $36.14 | $2.68 |
Market Cap | — | $1.07B |
Enterprise Value | — | $1.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $41.63, up 0.43% with bullish technical signals from moving averages and strong trend strength (ADX 39.69). The stock faces resistance at $42 with support at $41. Recent coverage highlights institutional interest in Cathie Wood's and Bill Ackman's overlapping investments in Magnificent Seven stocks.
The ETF's outlook is supported by technical momentum but lacks fundamental financial data disclosure. Key risks include market volatility and dependency on top holdings performance. Institutional overlap suggests confidence in selected growth stocks, though valuation metrics remain undisclosed.
SANA Biotechnology trades at $3.85, down 2.04% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows significant losses with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve in 2026. Recent news highlights clinical data presentations and a $69M stock sale via ATM facility in May 2026.
Despite heavy losses, analyst sentiment is strongly bullish with 82% buy ratings, reflecting optimism for SANA's engineered cell therapies. Key risks include sustained cash burn and clinical trial outcomes. The stock's appeal hinges on pipeline success, making it suitable for risk-tolerant investors betting on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
